LAM Pharmaceutical re-launches sexual dysfunction treatment products

By Angela McDaniels

Seattle, Nov. 22 - LAM Pharmaceutical Corp. said it has re-launched its sexual dysfunction treatment products, which are based on LAM's IPM Ionic Polymer Matrix.

Following the cancellation of the license to Ixora Biomedical for non-payment, LAM has granted a worldwide license (with the notable exception of China) for the sexual dysfunction treatment product group to marketing company Exoris Inc.

The first product marketed under the Exoris brand will be LAM's patented female sexual enhancement gel, the company said.

"In all my years of marketing products and services, marketing the LAM female sexual enhancement product will be most challenging. We will be utilizing infomercials and internet marketing to develop Exoris into a leading brand within the next two years," Exoris chief executive officer Howard Deverett said in a company news release.

"LAM is confident that Exoris' financial resources and global marketing expertise will translate into significant licensing revenue for LAM. We will do our utmost to assist Exoris to meet its sales commencement target date of April 2006," LAM president and chief executive officer Joseph T. Slechta said in the release.

LAM Pharmaceutical is a biomedical company based in Lewiston, N.Y., that develops wound-healing and transdermal drug delivery systems.

Exoris Inc. is an international distribution company with headquarters in the Cayman Islands and a main operation facility in Florida. Exoris' primary business focus is to distribute LAM sexual dysfunction treatment products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.